The combination regimen delivered better overall survival and response rates among patients with myelodysplastic syndromes (MDS). Although hypomethylating agents (HMAs) such as 5-azacytidine (AZA ...

The scientists show that the gene can be reactivated by treatment with an existing drug, 5-azacytidine. The results suggest that 5-azacytidine may function as targeted therapy for ALL in children.

A recent study discovered that applying 5-Azacytidine, a DNA methylation inhibitor, significantly reduces tomato susceptibility to gray mold, a common postharvest fungal disease.

SUMOylation is a post-translational modification implicated in DNA damage repair that has been linked to the lack of efficacy of some therapies commonly used for the treatment of leukemia.

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study) The following represents ...

Treatment with ruxolitinib plus azacytidine yielded encouraging spleen response rates and improvement in bone marrow fibrosis among patients with myelofibrosis, according an open-label, single-arm ...

The standard dosing schedule for hypomethylating agents, such as azacytidine, is 7 days, but some patients are given a 5-day dosing schedule, with little evidence to guide these decisions.